Twenty-one reference compounds. One format: a pre-portioned HPMC capsule, ready for the oral-route experiments that vials were never designed for. Every batch independently tested in the EU, issued with a lot-specific Certificate of Analysis, and shipped from our Slovakia warehouse to laboratories across Europe.
All materials on this page are supplied for research use only (RUO) / in vitro use by Condor Research (Atrio Sciences s.r.o., Slovakia). They are not drugs, food supplements or cosmetics; they are not for human or veterinary use; and they carry no therapeutic, diagnostic or dosing claim. The capsule format does not imply suitability for human ingestion.
Why a capsule format exists in research
The capsule is a research tool, not a convenience upgrade. Its specific function is to give investigators a consistent, pre-measured, dry unit for experiments where the variable under study is the oral route itself: bioavailability, intestinal stability, first-pass metabolism, pharmacokinetics in validated animal models.1 A lyophilised vial, by contrast, requires reconstitution and is optimised for solution-based and in-vitro assays where the investigator controls the working concentration.2
The honest caveat — stated prominently in the literature — is that oral delivery of peptides remains one of the hardest unsolved problems in pharmaceutical research. The barriers are well characterised: intestinal proteolysis cleaves peptide bonds before absorption, and epithelial permeability for large, hydrophilic molecules is characteristically low, producing very limited oral bioavailability for most sequences.12 A capsule does not solve those barriers. It makes them measurable, which is precisely why the format is an active subject of study.
The capsule format is not an endorsement of human ingestion — it is the format that makes the failure of oral bioavailability something you can measure and characterise.
Quality: what every batch includes
| What you get | How it is established |
|---|---|
| Independent third-party testing | An EU laboratory in Czechia — separate from the seller — characterises each lot before it is listed. |
| HPLC purity | ≥99% for single-compound capsules; reported per component for combination capsules. |
| Mass-spectrometry identity | MS confirms observed mass matches expected mass for peptide-based capsules. |
| Lot-specific COA | Certificate of Analysis carries the batch/lot number — traceable to the material you receive. |
| HPMC shell | Hydroxypropyl methylcellulose (plant-derived) hard capsule; no gelatin. |
| EU storage & dispatch | Held in our Nitra, Slovakia warehouse; shipped via Packeta, DPD or DHL under DAP (Incoterms 2020). |
The purity specification describes the HPLC result for that lot under the laboratory’s stated method. It is an analytical measurement — it does not speak to safety or efficacy in any use context. For a detailed explanation of what a COA contains and what the numbers mean, see How to Read a Certificate of Analysis for a Research Compound.
The collection: 21 encapsulated reference compounds
The catalogue spans four research areas: peptide repair and cytoprotection, Khavinson-lineage bioregulators, metabolic and body-composition research, and non-peptide nootropics. All formats are HPMC capsules; purity documentation is as stated above.
Peptide cytoprotection and repair
| Compound | Class | Research context (preclinical) |
|---|---|---|
| BPC-157 Arginate Capsules | Synthetic pentadecapeptide · arginate salt form | BPC-157 arginate is studied as a chemically distinct, more acid-stable salt of the standard acetate form, examined in preclinical cytoprotection and tissue-repair models where oral-route stability is the experimental variable.3 |
| TB-500 Capsules | Full-length thymosin β4 (43 aa) | Thymosin β4 is investigated for actin sequestration and cell-migration signalling in repair models; the capsule format is used to study oral-route handling of this full-length sequence.4 |
| BPC-157 Arginate + TB-500 Capsules | Combination peptide capsule | Combination of the two cytoprotective peptides in capsule form; purity reported per component. Used where oral co-delivery is the study design variable.34 |
| KPV Capsules | C-terminal α-MSH tripeptide (Lys-Pro-Val) | KPV, the C-terminal tripeptide of α-melanocyte-stimulating hormone, is studied for anti-inflammatory signalling in intestinal mucosa models; the oral capsule format is relevant to its intestinal research context.5 |
| Larazotide Capsules | Tight-junction modulator octapeptide (AT1001) | Larazotide acetate (AT1001) reached Phase III trials as an oral tight-junction modulator; it is studied in intestinal-permeability models and is one of the few oral peptide reference compounds with clinical trial data behind the oral-route rationale.6 |
Khavinson bioregulator peptides
The Khavinson bioregulators are short (2–4 residue) oligopeptides developed by Vladimir Khavinson’s group at the Saint-Petersburg Institute of Bioregulation and Gerontology and studied as putative tissue-specific genetic-level regulators.7 They represent an active and contested area of longevity and bioregulation research. Evidence is overwhelmingly preclinical, and most compounds lack data from randomised controlled trials in humans.
| Compound | Peptide / target tissue | Research context (preclinical) |
|---|---|---|
| Epitalon Capsules | Ala-Glu-Asp-Gly (tetrapeptide) · pineal gland | Studied in telomerase activation models, circadian rhythm research and ageing endpoints in preclinical systems.8 |
| Pinealon Capsules | Glu-Asp-Arg (tripeptide) · brain / pineal | Investigated in neuroprotection and brain ageing models within the Khavinson bioregulator framework.9 |
| Vesugen Capsules | Lys-Glu-Asp (tripeptide) · vascular endothelium | Studied in vascular research, specifically in models of endothelial ageing and atherosclerosis-related endpoints.10 |
| Cortagen Capsules | Ala-Glu-Asp-Pro (tetrapeptide) · cortex / nervous system | Studied as a peptide bioregulator in neurological and metabolic-correction contexts within the broader Khavinson bioregulator research programme.11 |
Copper-binding peptides
| Compound | Structure | Research context (preclinical) |
|---|---|---|
| GHK-Cu Capsules | Gly-His-Lys copper complex (tripeptide) | GHK-Cu is studied in tissue-remodelling, extracellular-matrix and wound-healing research; oral bioavailability of the copper-peptide complex is an open research question.12 |
| AHK-Cu Capsules | Ala-His-Lys copper complex (tripeptide) | AHK-Cu is studied in hair follicle and dermal research contexts; the tripeptide-copper complex is structurally analogous to GHK-Cu with a distinct tissue-targeting hypothesis.13 |
Metabolic and body-composition research
| Compound | Class | Research context (preclinical / clinical literature) |
|---|---|---|
| AOD-9604 Capsules | hGH lipolytic fragment (amino acids 176–191) | AOD-9604 is studied as an isolated fragment of the C-terminal region of human growth hormone that retains lipolytic activity in preclinical fat-metabolism models without the full GH receptor agonism of intact hGH.14 |
| Enclomiphene Capsules | Trans-isomer of clomiphene citrate · selective oestrogen receptor modulator | Enclomiphene is the trans-isomer of clomiphene, studied as a selective oestrogen receptor modulator in the hypothalamic-pituitary-gonadal axis; it reached clinical investigation for male hypogonadism.15 |
| Tesofensine Capsules | Triple monoamine reuptake inhibitor | Tesofensine inhibits reuptake of serotonin, dopamine and noradrenaline; it was investigated in randomised trials for obesity treatment and remains a reference compound for hypothalamic appetite-regulation research.16 |
| 5-Amino-1MQ Capsules | NNMT inhibitor (small molecule) | 5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), studied in adipogenesis and metabolic regulation models where NNMT activity is implicated in the methyl-group economy of energy metabolism.17 |
| SLU-PP-332 Capsules | Pan-ERR agonist (small molecule) | SLU-PP-332 activates oestrogen-related receptors α, β and γ, which coordinate oxidative-phosphorylation gene programmes in skeletal muscle; studied as an exercise-mimetic in preclinical metabolic models.18 |
Non-peptide nootropics and cognitive research compounds
5 distinct non-peptide mechanisms are represented in the nootropic capsule sub-collection — from mitochondrial electron-transfer modulation to MAO-B inhibition to HGF/c-Met signalling — making this the broadest mechanistic range available in encapsulated format from a single EU supplier.
| Compound | Mechanism class | Research context (preclinical) |
|---|---|---|
| NMN Capsules | NAD+ precursor (β-nicotinamide mononucleotide) | NMN is the direct precursor to NAD+; an NIH-registered, randomised trial in prediabetic postmenopausal women observed increases in skeletal-muscle NAD+ levels and improved insulin sensitivity, published in Science (2021).19 |
| Methylene Blue Capsules | Mitochondrial electron-transfer enhancer / MAO inhibitor | Methylene blue’s redox-cycling activity in the mitochondrial electron-transport chain has been studied in neuroprotection and cognitive-function models; Gonzalez-Lima and colleagues positioned mitochondrial respiration enhancement as a tractable target for cognitive research.20 |
| 9-Me-BC Capsules | β-carboline alkaloid · MAO-B inhibitor / neurotrophic | 9-Methyl-β-carboline inhibits monoamine oxidase activity and has been shown in cell models to stimulate neurotrophic-factor expression by astrocytes, placing it in the dopaminergic neuroprotection research category.21 |
| Dihexa Capsules | Peptidomimetic HGF/c-Met agonist | Dihexa (PNB-0408) is a low-molecular-weight peptidomimetic derived from angiotensin IV; its procognitive effects in rodent models were shown by McCoy et al. to depend on activation of the hepatocyte growth factor / c-Met signalling pathway and synaptogenesis.22 |
| J-147 Capsules | Curcumin-derived neuroprotective compound · ATP synthase target | J-147 is a synthetic derivative of curcumin developed in the Schubert laboratory; work published in eLife identified its molecular target as the mitochondrial ATP synthase (subunit ATP5A), making it a tool compound for mitochondrial ageing research.23 |
Evidence for all compounds above is overwhelmingly preclinical (cell and animal models). Where human trial data exist in the published literature, they are described as observed findings in the cited studies — not as predictions of effect in any reader. None of these materials are approved drugs (in the EU or elsewhere) for the research contexts described.
Encapsulated compounds: at a glance
| Product | Format | Research area | Product page |
|---|---|---|---|
| BPC-157 Arginate Capsules | HPMC capsule | Cytoprotection / oral stability | View |
| TB-500 Capsules | HPMC capsule | Tissue repair / actin dynamics | View |
| BPC-157 Arginate + TB-500 Capsules | Combination HPMC capsule | Cytoprotection combination | View |
| KPV Capsules | HPMC capsule | Intestinal inflammation research | View |
| Larazotide Capsules | HPMC capsule | Tight-junction / intestinal permeability | View |
| Epitalon Capsules | HPMC capsule | Longevity / telomerase | View |
| Pinealon Capsules | HPMC capsule | Neuroprotection / brain ageing | View |
| Vesugen Capsules | HPMC capsule | Vascular endothelium | View |
| Cortagen Capsules | HPMC capsule | Nervous system repair | View |
| GHK-Cu Capsules | HPMC capsule | Tissue remodelling / ECM | View |
| AHK-Cu Capsules | HPMC capsule | Hair follicle / dermal research | View |
| AOD-9604 Capsules | HPMC capsule | Lipolysis / fat metabolism | View |
| Enclomiphene Capsules | HPMC capsule | HPG axis / SERM research | View |
| Tesofensine Capsules | HPMC capsule | Appetite regulation / triple reuptake | View |
| 5-Amino-1MQ Capsules | HPMC capsule | NNMT inhibition / metabolism | View |
| SLU-PP-332 Capsules | HPMC capsule | ERR agonism / exercise mimetic | View |
| NMN Capsules | HPMC capsule | NAD+ metabolism | View |
| Methylene Blue Capsules | HPMC capsule | Mitochondrial respiration | View |
| 9-Me-BC Capsules | HPMC capsule | Dopaminergic / neuroprotection | View |
| Dihexa Capsules | HPMC capsule | Synaptogenesis / HGF/c-Met | View |
| J-147 Capsules | HPMC capsule | ATP synthase / ageing models | View |
Full catalogue: Encapsulated Compounds category. Compare with the Peptides in Vials collection for lyophilised format options.
How to choose: capsule versus lyophilised vial
The format question is not about convenience — it is about experimental design. Use a vial when you need to control working concentration: the reconstituted solution can be diluted to any point on a dose-response curve, and the lyophilised state provides the best dry-form stability.2 Use a capsule when the oral route is itself the variable: when you are asking whether a compound survives the gastrointestinal tract and reaches its target in a validated animal model, the pre-measured capsule unit is the appropriate experimental object.1
For a full treatment of this decision, see our research article: Capsule vs Vial Research Compounds: Which Format Fits Your Study Design?
Frequently asked questions
What is an encapsulated research compound?
An encapsulated research compound is a reference material — peptide or small molecule — enclosed in a pre-portioned HPMC (hydroxypropyl methylcellulose) hard-shell capsule. The capsule format delivers a fixed quantity per unit and requires no reconstitution, making it the appropriate format for oral-route bioavailability and pharmacokinetic experiments in validated animal models. It is not a finished drug, food supplement or therapeutic product, and is not intended for human or veterinary use.
Why choose the capsule format over a lyophilised vial?
The two formats serve different experimental intentions. A lyophilised vial gives full concentration control after reconstitution and suits solution-based, in-vitro and analytical work. A capsule delivers a fixed, pre-measured dry unit without reconstitution — the correct choice when the oral route itself is the research variable (bioavailability, pharmacokinetics, oral stability) and when the protocol calls for a consistent unit in an in-vivo model. See the full comparison: Capsule vs Vial Research Compounds.
Are encapsulated research compounds legal to order in Europe?
Reference materials supplied strictly for laboratory and in-vitro investigation, documented with SDS/CLP under REACH where applicable and without any human-use claim, are sold and used as reagents within the EU. The legal picture depends on the specific compound and on whether the research-use framing is genuine. Researchers are responsible for compliance in their own jurisdiction. Condor maintains the RUO frame consistently; none of our materials are supplied for consumption.
What quality documentation comes with each capsule batch?
Each batch is tested by an independent third-party laboratory in Czechia before listing. HPLC confirms purity (≥99% for single-compound capsules; per-component for combination capsules). Mass spectrometry confirms identity for peptide-based capsules. A lot-specific Certificate of Analysis — carrying the batch number — ships with the order and is available on request prior to purchase. Full methodology is described on Quality & Third-Party Testing.
How are encapsulated compounds shipped within Europe?
Inventory is held in our EU warehouse in Nitra, Slovakia, and dispatched via Packeta, DPD or DHL under DAP (Incoterms 2020). Free shipping applies on orders of €150 or more. EU-based dispatch minimises customs friction for EU researchers.
Can I order both vials and capsules together?
Yes. Capsules and vials are sold through the same catalogue and can be combined in a single order. The free-shipping threshold (≥€150) applies to the combined order total.
Who operates Condor Research?
Condor Research is operated by Atrio Sciences s.r.o., IČO 57 669 651, Hornočermánska 1556/76, 949 01 Nitra, Slovakia. Reach us at info@condorresearch.com.
All products supplied by Condor Research (Atrio Sciences s.r.o.) are for research use only / in vitro use. They are not for human or veterinary use, not drugs, foods or cosmetics, and not for diagnostic or therapeutic purposes. Nothing on this page is dosing, medical or consumption advice. The capsule format does not imply or suggest suitability for human ingestion.
Condor Research · Scientific desk
References
- Muheem A, et al. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm J. 2016. PMID: 27330372. https://pubmed.ncbi.nlm.nih.gov/27330372/
- Crommelin DJA, et al. Formulating drug products for the route of administration: pharmaceutical considerations. Drug Discovery Today. 2022. DOI: 10.1016/j.drudis.2021.11.014. https://doi.org/10.1016/j.drudis.2021.11.014
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response. Gut and Liver. 2020. PMID: 31158953. https://pubmed.ncbi.nlm.nih.gov/31158953/
- Tokura Y, et al. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. J Biochem. 2011. PMID: 20880960. https://pubmed.ncbi.nlm.nih.gov/20880960/
- Sangwan N, et al. Self-cross-linked hydrogel of cysteamine-grafted γ-polyglutamic acid stabilized tripeptide KPV for alleviating TNBS-induced ulcerative colitis. ACS Biomater Sci Eng. 2022. PMID: 34547895. https://pubmed.ncbi.nlm.nih.gov/34547895/
- Vespasiani-Gentilucci U, et al. Ameliorative effects of larazotide acetate on intestinal permeability and bacterial translocation in acute pancreatitis model in rats. Dig Dis Sci. 2014. PMID: 38441784. https://pubmed.ncbi.nlm.nih.gov/38441784/
- Khavinson VK, et al. DNA double-helix binds regulatory peptides similarly to transcription factors. Neuro Endocrinol Lett. 2005. PMID: 15990728. https://pubmed.ncbi.nlm.nih.gov/15990728/
- Khavinson VK, et al. Effects of bioactive tetrapeptides on free-radical processes. Bull Exp Biol Med. 2008. PMID: 18239817. https://pubmed.ncbi.nlm.nih.gov/18239817/
- Khavinson VK, et al. Neuroprotective effects of peptide bioregulators in people of various ages. Adv Gerontol. 2014. PMID: 24738258. https://pubmed.ncbi.nlm.nih.gov/24738258/
- Khavinson VK, et al. Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis. Adv Gerontol. 2017. PMID: 28539025. https://pubmed.ncbi.nlm.nih.gov/28539025/
- Khavinson VK, et al. Cortexin and cortagen as correcting agents in functional and metabolic disorders. Eksp Klin Farmakol. 2011. PMID: 21476278. https://pubmed.ncbi.nlm.nih.gov/21476278/
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PMID: 18644225. https://pubmed.ncbi.nlm.nih.gov/18644225/
- Sim GS, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. PMID: 17703734. https://pubmed.ncbi.nlm.nih.gov/17703734/
- Ng FM, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knockout mice. Endocrinology. 2001. PMID: 11713213. https://pubmed.ncbi.nlm.nih.gov/11713213/
- Khera M, et al. Changes in serum testosterone after sublingual enclomiphene citrate combined with a mineral oxide delivery system: a retrospective case series. Cureus. 2026. PMID: 42170362. https://pubmed.ncbi.nlm.nih.gov/42170362/
- Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008. PMID: 18950853. https://pubmed.ncbi.nlm.nih.gov/18950853/
- Alston L, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep. 2022. PMID: 35013352. https://pubmed.ncbi.nlm.nih.gov/35013352/
- Giudice J, et al. Pharmacological activation of ERRα/β/γ as an exercise mimetic: potential therapeutic applications. Rev Med Chil. 2025. PMID: 42024694. https://pubmed.ncbi.nlm.nih.gov/42024694/
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. PMID: 33888596. https://pubmed.ncbi.nlm.nih.gov/33888596/
- Gonzalez-Lima F, Barksdale BR, Rojas JC. Mitochondrial respiration as a target for neuroprotection and cognitive enhancement. Biochem Pharmacol. 2014. PMID: 24316434. https://pubmed.ncbi.nlm.nih.gov/24316434/
- Haas M, et al. 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes. J Neural Transm (Vienna). 2020. PMID: 32285253. https://pubmed.ncbi.nlm.nih.gov/32285253/
- McCoy AT, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2013. PMID: 25187433. https://pubmed.ncbi.nlm.nih.gov/25187433/
- Goldberg J, et al. Elevating acetyl-CoA levels reduces aspects of brain aging. eLife. 2019. PMID: 31742554. https://pubmed.ncbi.nlm.nih.gov/31742554/